Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 9/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.65 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.48 |
| ▸ | FDPS | P14324 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23576181 | 1.00 | DNM1 (0.65) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL1785589 | 1.00 | DNM1 (0.65) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL1782745 | 1.00 | DNM1 (0.65) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL16827196 | 1.00 | DNM1 (0.65) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL27755113 | 1.00 | DNM1 (0.65) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL1783973 | 0.95 | DNM1 (0.57) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL1900711 | 0.95 | DNM1 (0.57) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL4059409 | 0.95 | DNM1 (0.57) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL23576728 | 0.95 | DNM1 (0.57) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL11772114 | 0.95 | DNM1 (0.57) | DNM1TSHRMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3189091-A2 | MAIN CHAIN POLYAMINES | Genzyme Corporation (US) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016007821-A2 | MAIN CHAIN POLYAMINES | GENZYME CORPORATION (US) | 2016-01-14 | — | — | WO | disclosed |
| US-20110117164-A1 | Use of Additive Sites to Control Nitric Oxide Release from Nitric Oxide Donors Contained within Polymers | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR | 2011-05-19 | — | — | US | disclosed |
| US-20060008529-A1 | Use of additive sites to control nitric oxide release from nitric oxide donors contained within polymers | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117164-A1 | Use of Additive Sites to Control Nitric Oxide Release from Nitric Oxide Donors Contained within Polymers | NOS1, NOS2, NOS3 | DNM1 2870/4885TSHR 4279/4885MEN1 2883/4885 |
| US-20060008529-A1 | Use of additive sites to control nitric oxide release from nitric oxide donors contained within polymers | NOS1, NOS2, NOS3 | DNM1 2870/4885TSHR 4279/4885MEN1 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.